Please wait while the formulary information is being retrieved.
Drug overview for FLUBLOK 2025-2026 (influenza virus vaccine tv 2025-26(18 yrs and older)rcmb/pf):
Generic name: INFLUENZA VIRUS VACCINE TV 2025-26(18 YRS AND OLDER)RCMB/PF (IN-floo-EN-za)
Drug class: Influenza Vaccine
Therapeutic class: Biologicals
Influenza vaccine live intranasal (LAIV3) stimulates active immunity to influenza virus infection. The vaccine contains live, attenuated (cold-adapted) influenza virus types A and type B representing strains likely to circulate in the US during the upcoming influenza season.
No enhanced Uses information available for this drug.
Generic name: INFLUENZA VIRUS VACCINE TV 2025-26(18 YRS AND OLDER)RCMB/PF (IN-floo-EN-za)
Drug class: Influenza Vaccine
Therapeutic class: Biologicals
Influenza vaccine live intranasal (LAIV3) stimulates active immunity to influenza virus infection. The vaccine contains live, attenuated (cold-adapted) influenza virus types A and type B representing strains likely to circulate in the US during the upcoming influenza season.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for FLUBLOK 2025-2026 (influenza virus vaccine tv 2025-26(18 yrs and older)rcmb/pf) have been approved by the FDA:
Indications:
Influenza vaccination
Professional Synonyms:
Vaccination to prevent influenza
Indications:
Influenza vaccination
Professional Synonyms:
Vaccination to prevent influenza
The following dosing information is available for FLUBLOK 2025-2026 (influenza virus vaccine tv 2025-26(18 yrs and older)rcmb/pf):
The dosing schedule (i.e., number of doses) of seasonal influenza vaccine live intranasal for prevention of seasonal influenza depends on the individual's age and vaccination history.
A single dose of seasonal influenza vaccine live intranasal consists of the entire contents (0.2 mL) of the sprayer (approximately one-half of the contents or 0.1 mL in each nostril).
A single dose of seasonal influenza vaccine live intranasal consists of the entire contents (0.2 mL) of the sprayer (approximately one-half of the contents or 0.1 mL in each nostril).
Influenza vaccine live intranasal is administered intranasally using the prefilled, single-use sprayer supplied by the manufacturer. The single-use sprayer is equipped with a nozzle that produces a fine mist that is primarily deposited in the nose and nasopharynx.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| FLUBLOK 2025-2026 SYRINGE | Maintenance | Adults inject 0.5 milliliter (135 mcg) by intramuscular route once |
No generic dosing information available.
The following drug interaction information is available for FLUBLOK 2025-2026 (influenza virus vaccine tv 2025-26(18 yrs and older)rcmb/pf):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for FLUBLOK 2025-2026 (influenza virus vaccine tv 2025-26(18 yrs and older)rcmb/pf):
Drug contraindication overview.
*History of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein. *History of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any influenza vaccine. *Children and adolescents 2 through 17 years of age receiving aspirin or aspirin-containing therapy because of the association of Reye's syndrome with aspirin use and wild-type influenza infection.
*History of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein. *History of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any influenza vaccine. *Children and adolescents 2 through 17 years of age receiving aspirin or aspirin-containing therapy because of the association of Reye's syndrome with aspirin use and wild-type influenza infection.
There are 0 contraindications.
There are 1 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Guillain-barre syndrome |
There are 0 moderate contraindications.
The following adverse reaction information is available for FLUBLOK 2025-2026 (influenza virus vaccine tv 2025-26(18 yrs and older)rcmb/pf):
Adverse reaction overview.
Adverse effects reported more frequently in adults 18 through 49 years of age receiving seasonal influenza vaccine live intranasal than in those receiving placebo include runny nose (44%), headache (40%), sore throat (28%), tiredness/weakness (26%), muscle aches (17%), cough (14%), chills (9%), nasal congestion (9%), and sinusitis (4%). Adverse effects reported more frequently in children 2 through 6 years of age receiving seasonal influenza vaccine live intranasal than in those receiving placebo include runny nose/nasal congestion (58%), decreased appetite (21%), irritability (21%), fever (16%), lethargy (14%), sore throat (11%), headache (9%), muscle aches (6%), and chills (4%). Similar adverse effects were reported in older children and adolescents through 17 years of age; in addition, abdominal pain was reported in 12% and decreased activity reported in 6% of vaccine recipients.
Adverse effects reported more frequently in adults 18 through 49 years of age receiving seasonal influenza vaccine live intranasal than in those receiving placebo include runny nose (44%), headache (40%), sore throat (28%), tiredness/weakness (26%), muscle aches (17%), cough (14%), chills (9%), nasal congestion (9%), and sinusitis (4%). Adverse effects reported more frequently in children 2 through 6 years of age receiving seasonal influenza vaccine live intranasal than in those receiving placebo include runny nose/nasal congestion (58%), decreased appetite (21%), irritability (21%), fever (16%), lethargy (14%), sore throat (11%), headache (9%), muscle aches (6%), and chills (4%). Similar adverse effects were reported in older children and adolescents through 17 years of age; in addition, abdominal pain was reported in 12% and decreased activity reported in 6% of vaccine recipients.
There are 15 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
Anaphylaxis Angioedema Bell's palsy Brachial plexus disorder Cellulitis Dyspnea Encephalopathy Guillain-barre syndrome Hypersensitivity drug reaction Myelitis Optic neuritis Serum sickness Stevens-johnson syndrome Thrombocytopenic disorder Vasculitis |
There are 34 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Bruising Chills Erythema Fatigue Headache disorder Induration of skin Injection site pain Injection site sequelae Malaise Myalgia Pruritus of skin |
Appetite changes Arthralgia Cough Diarrhea Ecchymosis Fever Injection site erythema Injection site inflammation Nausea Pharyngitis Vomiting |
| Rare/Very Rare |
|---|
|
Back pain Dizziness Extensive limb swelling after injection Flushing Lymphadenopathy Neuralgia Pain in oropharynx Paresthesia Seizure disorder Skin rash Syncope Urticaria |
The following precautions are available for FLUBLOK 2025-2026 (influenza virus vaccine tv 2025-26(18 yrs and older)rcmb/pf):
Safety and efficacy of influenza vaccine live intranasal have been established only in children 2 years of age or older. The effectiveness of influenza vaccine live intranasal in children 6 through 17 years of age is supported by demonstration of efficacy in younger children 6-71 months of age and effectiveness in adults 18-49 years of age. Influenza vaccine live intranasal should not be administered to infants younger than 24 months of age. An increased incidence of wheezing and hospitalization has been reported in a clinical trial in infants 6 through 23 months of age+ who received influenza vaccine live intranasal compared with those who received parenteral influenza vaccine inactivated.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
The manufacturer states that influenza vaccine live intranasal is not absorbed systemically following intranasal administration and use in pregnant women is not expected to result in fetal exposure. Animal reproduction studies performed with influenza vaccine live intranasal have not revealed evidence of harm to the fetus. Experts state that influenza vaccine live intranasal should not be used during pregnancy.
Women who are pregnant or who might become pregnant during the influenza season should be vaccinated using any licensed, age-appropriate, inactivated influenza vaccine (i.e., influenza virus vaccine inactivated or influenza vaccine recombinant).
Women who are pregnant or who might become pregnant during the influenza season should be vaccinated using any licensed, age-appropriate, inactivated influenza vaccine (i.e., influenza virus vaccine inactivated or influenza vaccine recombinant).
The manufacturer states that influenza vaccine live intranasal is not absorbed systemically following intranasal administration and distribution into milk is not expected. ACIP states that live, attenuated virus vaccines generally do not pose any unusual risks for women who are breast-feeding or their breast-fed infants. Although live, attenuated viruses in vaccines can replicate in the mother, the majority of live vaccine viruses are not distributed into milk.
Influenza vaccine live intranasal is not indicated for use in geriatric individuals 65 years of age or older.
The following prioritized warning is available for FLUBLOK 2025-2026 (influenza virus vaccine tv 2025-26(18 yrs and older)rcmb/pf):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for FLUBLOK 2025-2026 (influenza virus vaccine tv 2025-26(18 yrs and older)rcmb/pf)'s list of indications:
| Influenza vaccination | |
| Z23 | Encounter for immunization |
Formulary Reference Tool